NTI's Principal Activity is the conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of its proprietary cannabis strains. commercialising Mente, the worldï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½ï¿½?s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+117.37%|
|vs ASX 200 (1yr)||+99.08%|
|ASX Rank||1,465 of 2,319|
|Sector Rank||131 of 198|
Neurotech International Limited (NTI) is a medical device and solutions company whose primary mission is to improve the lives of people with neurological conditions. NTI operates in one segment being Medical Device Development and Distribution. The Company incorporated in Australia, operating through its wholly-Owned, malta-based subsidiary, AAT Research Limited.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Professor Allan Cripps||Non-Executive Director||May 2021||
Professor Allan Cripps
Prof Cripps is currently a Prof Emeritus in the School of Medicine and Dentistry and the Menzies Health Institute Queensland at Griffith University, Australia. He is a member of the Infection and Immunity Research Team at the Menzies Health Institute Queensland at Griffith University, Australia. He is recognised nationally and internationally as a distinguished academic, clinical scientist and health services leader and has made significant contributions in immunology, vaccine development, diagnostics health services delivery and professional health education. The focus of Prof Cripps' research activities over the last 5 decades have been in the field of immunology and inflammation. In 2015 he was awarded an Officer of the Order of Australia (AO) in recognition of his contributions to mucosal immunization, public health and higher education. Prof Cripps has experience in the development of immunity in children and mucosal immune mechanisms, in recent years he has made a significant contribution to the field of immunology through translational research and human clinical studies. Prof Cripps is also a co-inventor on several patents in the fields of diagnostic technology and vaccine protein antigens for respiratory infection. He has published over 325 peer reviewed scientific papers and presented at many national and international scientific conferences.
|Ms Krista Bates||Non-Executive Director||Apr 2021||
Ms Krista Bates
Ms Bates is an experienced non-executive and executive director of listed companies (Australian Stock Exchange and London Stock Exchange) and various private companies in multiple jurisdictions. She is commercially experienced, particularly talented in turnarounds, structuring, risk mitigation and strategic roll-out of commercial initiatives. She has an exceptional legal background with over 23 years' experience in the legal market, with experience working in emerging markets in both a commercial and legal capacity. Ms Bates is currently a Non-executive Director of AusCann Holdings (ASX:AC8), Australian Cannabis Ventures and Australia-Africa Minerals & Energy Group. She was also a Corporate Partner at Lavan law firm, where she is Head of Mining & Resources Group and Head of Medical Cannabis Group. She is the founder of KB Corporate Advisors which provides legal and corporate advisory services.
|Mr Brian Willoughby Leedman||Non-Executive Chairman,Non-Executive Director||Oct 2020||
Mr Brian Willoughby Leedman
Non-Executive Chairman,Non-Executive Director
Mr Leedman is formerly the Chairman (WA) of Ausbiotech, Founder and Executive Director of ResApp Health, Founder of Oncosil Medical and Biolife Sciences Limited (acquired by Imugene Limited) and Non-executive Director of Alcidion Corporation and former Chairman of NeuroScientific Biopharmaceuticals. He is presently the Chairman of NeuroScientific Biopharmaceuticals and Chairman of Nutritional Growth Solutions. He has over 15 years' experience in the biotechnology sector.
|Mr Winton William Willesee||Non-Executive Director||Apr 2019||
Mr Winton William Willesee
Mr Willesee is an experienced company director and secretary with over 20 years' experience in various roles within the Australian capital markets. Mr Willesee has experience with ASX listed and other companies over a range of industries having been involved with many successful ventures from early stage through to large capital development projects. He has a core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance
|Mr Mark Davies||Non-Executive Director||Apr 2019||
Mr Mark Davies
Mr Davies has over 20 years' experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. Mark specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.
|Ms Erlyn Dale||Company Secretary||Apr 2019|
NTI directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|14/07/21||Allan Cripps||Buy||+180,000||$0.056||$10,017||On-market trade|
|14/07/21||Krista Bates||Buy||+180,000||$0.056||$10,044||On-market trade|
|22/06/21||Brian Leedman||Buy||+933,589||$0.054||$49,961||On-market trade|
|13/04/21||Krista Bates||Buy||+270,000||$0.074||$19,980||On-market trade|
|17/12/20||Winton Willesee||Issued||2,000,000||$0.056||$112,000||Issue of options|
|17/12/20||Mark Davies||Issued||2,000,000||$0.056||$112,000||Issue of options|
|17/12/20||Brian Leedman||Issued||20,000,000||$0.056||$1,120,000||Issue of options|
|05/10/20||Winton Willesee||Transfer||1,252,852||$0.013||$16,287||Off-market transfer|
|05/10/20||Winton Willesee||Issued||6,047,382||$0.008||$48,500||Director remuneration|
|30/09/20||Peter Griffiths||Issued||16,957,606||$0.008||$136,000||Director remuneration|
|30/09/20||David Cantor||Issued||4,551,122||$0.008||$36,499||Director remuneration|
|30/09/20||Mark Davies||Issued||7,793,017||$0.008||$62,499||Director remuneration|
|18/11/19||David Cantor||Buy||+2,000,000||$0.014||$28,000||As advised by the company|
|18/11/19||Mark Davies||Buy||+2,000,000||$0.014||$28,000||As advised by the company|
|18/11/19||Winton Willesee||Buy||+2,000,000||$0.014||$28,000||As advised by the company|
|18/11/19||Peter Griffiths||Buy||+11,929,754||$0.014||$167,017||As advised by the company|
|25/02/19||Peter O'Connor||Issued||503,100||$0.026||$13,081||Rights issue|
|25/02/19||Peter Griffiths||Issued||2,634,790||$0.03||$79,044||Rights issue|
|25/02/19||Simon Trevisan||Issued||3,333,334||$0.03||$100,000||Rights issue|
|25/02/19||Peter Griffiths||Issued||2,634,790||$0.026||$68,505||Rights issue|
|25/02/19||Peter O'Connor||Issued||503,100||$0.03||$15,093||Rights issue|
|25/02/19||Simon Trevisan||Issued||3,333,334||$0.026||$86,667||Rights issue|
|04/12/18||David Cantor||Issued||142,857||$0.14||$20,000||Issue of securities|
The current holdings of NTI directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
No Substantial Shareholders for NTI in our database.
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|12-11-20||J and J Bandy Nominees Pty Ltd||23,344,887||10.85||--|
|12-11-20||Shimano Ventures Limited||24,249,984||6.24||--|
|12-11-20||Jalaver Pty Ltd||22,645,178||10.52||--|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.